Rankings
▼
Calendar
AMLX Q2 2024 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMLX
Amylyx Pharmaceuticals, Inc.
$1B
Q2 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
-$1M
-101.0% YoY
Gross Profit
-$9M
845.5% margin
Operating Income
-$53M
5223.4% margin
Net Income
-$73M
7106.5% margin
EPS (Diluted)
$-1.07
QoQ Revenue Growth
-101.2%
Cash Flow
Operating Cash Flow
-$67M
Free Cash Flow
-$67M
Stock-Based Comp.
$10M
Balance Sheet
Total Assets
$332M
Total Liabilities
$71M
Stockholders' Equity
$261M
Cash & Equivalents
$75M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
-$1M
$98M
-101.0%
Gross Profit
-$9M
$93M
-109.3%
Operating Income
-$53M
$20M
-364.5%
Net Income
-$73M
$22M
-429.3%
← FY 2024
All Quarters
Q3 2024 →